Long-Acting Injectables: A New Solution for Nonadherence in Patients with Schizophrenia


Medication adherence challenges are exacerbated in patients with chronic medical and mental health conditions, with nonadherence reaching as high as 90% in those with schizophrenia. Long-acting injectable antipsychotics have been introduced to contend with poor adherence and improve clinical and economic outcomes. Learn more about them and how to select the right one for your patients with schizophrenia.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Describe the prevalence of medication nonadherence among patients with mental illness and the potential role of long-acting injectable (LAI) antipsychotics in improving adherence.
  2. Compare the currently available LAI antipsychotics.
  3. Discuss the clinical and economic advantages and disadvantages of LAI antipsychotics.
  4. Describe the role of pharmacists in ensuring medication adherence in patients using   LAI antipsychotics.
  5. Select the most appropriate LAI antipsychotic for a given patient case.


This activity is supported by an educational grant from Alkermes.

Susie Park, PHARMD
Associate Professor of Clinical Pharmacy
USC School of Pharmacy
Kelly Lee, PharmD, MAS, FCCP, BCPP
Professor and Associate Dean
University of California, San Diego
Learning Level: Level 2
Track: Specialty Pharmacy, Clinical Patient Care and Services
Session Time Slot(s): 
Friday, March 16
10:00 AM - 11:30 AM
Music City Center - Room 106A-C
ACPE Pharmacist: 0202-0000-18-062-L01-P
CEUs Pharmacist: 0.15
Activity Type: